Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All bromhexine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchBromhexineBromhexine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry

Peacock et al., bioRxiv, doi:10.1101/2021.12.31.474653
Jan 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
In Vitro study showing that omicron can efficiently enter cells via the endosomal route, independent of TMPRSS2.
4 preclinical studies support the efficacy of bromhexine for COVID-19:
Peacock et al., 3 Jan 2022, preprint, 10 authors.
In Vitro studies are an important part of preclinical research, however results may be very different in vivo.
This PaperBromhexineAll
The altered entry pathway and antigenic distance of the SARS-CoV-2 Omicron variant map to separate domains of spike protein
Thomas P Peacock, Jonathan C Brown, Jie Zhou, Nazia Thakur, Ksenia Sukhova, Joseph Newman, Ruthiran Kugathasan, Ada W C Yan, Wilhelm Furnon, Giuditta De Lorenzo, Vanessa M Cowton, Dorothee Reuss, Maya Moshe, Jessica L Quantrill, Olivia K Platt, Myrsini Kaforou, Arvind H Patel, Massimo Palmarini, Dalan Bailey, Wendy S Barclay
doi:10.1101/2021.12.31.474653
At the end of 2021 a new SARS-CoV-2 variant, Omicron, emerged and quickly spread across the world. It has been demonstrated that Omicron's high number of Spike mutations lead to partial immune evasion from even polyclonal antibody responses, allowing frequent re-infection and vaccine breakthroughs. However, it seems unlikely these antigenic differences alone explain its rapid growth; here we show Omicron replicates rapidly in human primary airway cultures, more so even than the previously dominant variant of concern, Delta. Omicron Spike continues to use human ACE2 as its primary receptor, to which it binds more strongly than other variants. Omicron Spike mediates enhanced entry into cells expressing several different animal ACE2s, including various domestic avian species, horseshoe bats and mice suggesting it has an increased propensity for reverse zoonosis and is more likely than previous variants to establish an animal reservoir of SARS-CoV-2. Unlike other SARS-CoV-2 variants, however, Omicron Spike has a diminished ability to induce syncytia formation. Furthermore, Omicron is capable of efficiently entering cells in a TMPRSS2-independent manner, via the endosomal route. We posit this enables Omicron to infect a greater number of cells in the respiratory epithelium, allowing it to be more infectious at lower exposure doses, and resulting in enhanced intrinsic transmissibility. .
Supplementary Figures Supplementary Figure S1 Supplementary Figure S2 -Different species ACE2 preference of different variants of concern. Receptor usage was screened using pseudoviruses expressing the indicated Spike proteins into 293Ts expressing the indicated ACE2 protein. Viral entry was measured by assaying luciferase activity (RLU) using the BrightGlo reagent (Promega).
References
Abdelnabi, SARS-CoV-2 variant of concern does not readily infect Syrian hamsters, The omicron, doi:10.1101/2021.12.24.474086
Bentley, SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19, bioRxiv, doi:10.1101/2021.12.26.474085
Braga, Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia, Nature, doi:10.1038/s41586-021-03491-6
Cameroni, Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift, bioRxiv, doi:10.1101/2021.12.12.472269
Cao, Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies, bioRxiv, doi:10.1101/2021.12.07.470392
Cele, SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection, medRxiv, doi:10.1101/2021.12.08.21267417
Conceicao, The SARS-CoV-2 Spike protein has a broad tropism for mammalian ACE2 proteins, PLoS Biol, doi:10.1371/journal.pbio.3001016
Corman, Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Eurosurveillance, doi:10.2807/1560-7917.ES.2020.25.3.2000045
David, A common <em>TMPRSS2</em> variant protects against severe COVID-19, medRxiv, doi:10.1101/2021.03.04.21252931
Dinnon, A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures, Nature, doi:10.1038/s41586-020-2708-8
Edie, Survey of human chromosome 21 gene expression effects on early development in Danio rerio. G3: Genes, Genomes, Genetics
Ferguson, Report 49 -Growth, population distribution and immune escape of Omicron in England
Hale, SARS-CoV-2 infection in free-ranging white-tailed deer, Nature, doi:10.1038/s41586-021-04353-x
Heurich, TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein, J Virol, doi:10.1128/jvi.02202-13
Hoffmann, Kleine-Weber, Pöhlmann, A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells, Mol Cell, doi:10.1016/j.molcel.2020.04.022
Hoffmann, The Omicron variant is highly resistant against antibody-mediated neutralization -implications for control of the COVID-19 pandemic, Cell, doi:10.1016/j.cell.2021.12.032
Ishikawa, Meng, Kondo, Iwamoto, Matsuda, Generation of a dual-functional split-reporter protein for monitoring membrane fusion using self-associating split GFP, Protein Eng Des Sel, doi:10.1093/protein/gzs051
Johnson, Furin Cleavage Site Is Key to SARS-CoV-2 Pathogenesis, bioRxiv, doi:10.1101/2020.08.26.268854
Liu, Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, bioRxiv, doi:10.1101/2021.12.14.472719
Mckay, Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice, Nat Commun, doi:10.1038/s41467-020-17409-9
Meng, SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion, doi:10.1101/2021.12.17.473248
Mlcochova, SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion, Nature, doi:10.1038/s41586-021-03944-y
Muruato, Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge, bioRxiv, doi:10.1101/2021.05.03.442357
Muus, Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics, Nature Medicine, doi:10.1038/s41591-020-01227-z
Newman, Neutralising antibody activity against SARS-CoV-2 variants, including Omicron, in an elderly cohort vaccinated with BNT162b2, medRxiv, doi:10.1101/2021.12.23.21268293
Ni, Structural analysis of the Spike of the Omicron SARS-COV-2 variant by Cryo-EM and implications for immune evasion, bioRxiv, doi:10.1101/2021.12.27.474250
Peacock, The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin, bioRxiv, doi:10.1101/2021.05.28.446163
Peacock, The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets, Nat Microbiol, doi:10.1038/s41564-021-00908-w
Planas, Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization, bioRxiv, doi:10.1101/2021.12.14.472630
Pulliam, Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa, medRxiv, doi:10.1101/2021.11.11.21266068
Puray-Chavez, Systematic analysis of SARS-CoV-2 infection of an ACE2-negative human airway cell, Cell Reports, doi:10.1016/j.celrep.2021.109364
Rihn, A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research, PLoS Biol, doi:10.1371/journal.pbio.3001091
Saito, Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation, Nature, doi:10.1038/s41586-021-04266-9
Thakur, Micro-fusion inhibition tests: quantifying antibody neutralization of virusmediated cell-cell fusion, Journal of General Virology, doi:10.1099/jgv.0.001506
Thakur, SARS-CoV-2 variants of concern Alpha, Beta, Gamma and Delta have extended ACE2 receptor host-ranges, bioRxiv, doi:10.1101/2021.11.23.469663
Viana, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa, medRxiv, doi:10.1101/2021.12.19.21268028
Winstone, The polybasic cleavage site in the SARS-CoV-2 spike modulates viral sensitivity to Type I interferon and IFITM2, J Virol, doi:10.1128/JVI.02422-20
Yin, Structures of the Omicron Spike trimer with ACE2 and an anti-Omicron antibody, bioRxiv, doi:10.1101/2021.12.27.474273
Zhou, Investigating SARS-CoV-2 surface and air contamination in an acute healthcare setting during the peak of the COVID-19 pandemic in London, Clin Infect Dis, doi:10.1093/cid/ciaa905
Zhou, Mutations that adapt SARS-CoV-2 to mustelid hosts do not increase fitness in the human airway, bioRxiv, doi:10.1101/2021.08.20.456972
{ 'institution': [{'name': 'bioRxiv'}], 'indexed': {'date-parts': [[2022, 1, 4]], 'date-time': '2022-01-04T05:54:12Z', 'timestamp': 1641275652490}, 'posted': {'date-parts': [[2022, 1, 3]]}, 'group-title': 'Microbiology', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'accepted': {'date-parts': [[2022, 1, 3]]}, 'abstract': '<jats:p>At the end of 2021 a new SARS-CoV-2 variant, Omicron, emerged and quickly spread ' 'across the world. It has been demonstrated that Omicrons high number of Spike mutations lead ' 'to partial immune evasion from even polyclonal antibody responses, allowing frequent ' 're-infection and vaccine breakthroughs. However, it seems unlikely these antigenic ' 'differences alone explain its rapid growth; here we show Omicron replicates rapidly in human ' 'primary airway cultures, more so even than the previously dominant variant of concern, Delta. ' 'Omicron Spike continues to use human ACE2 as its primary receptor, to which it binds more ' 'strongly than other variants. Omicron Spike mediates enhanced entry into cells expressing ' 'several different animal ACE2s, including various domestic avian species, horseshoe bats and ' 'mice suggesting it has an increased propensity for reverse zoonosis and is more likely than ' 'previous variants to establish an animal reservoir of SARS-CoV-2. Unlike other SARS-CoV-2 ' 'variants, however, Omicron Spike has a diminished ability to induce syncytia formation. ' 'Furthermore, Omicron is capable of efficiently entering cells in a TMPRSS2-independent ' 'manner, via the endosomal route. We posit this enables Omicron to infect a greater number of ' 'cells in the respiratory epithelium, allowing it to be more infectious at lower exposure ' 'doses, and resulting in enhanced intrinsic transmissibility.</jats:p>', 'DOI': '10.1101/2021.12.31.474653', 'type': 'posted-content', 'created': {'date-parts': [[2022, 1, 4]], 'date-time': '2022-01-04T02:25:13Z', 'timestamp': 1641263113000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial ' 'cultures and efficiently uses the endosomal route of entry.'], 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0001-7077-2928', 'authenticated-orcid': False, 'given': 'Thomas P.', 'family': 'Peacock', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-6849-3962', 'authenticated-orcid': False, 'given': 'Jonathan C', 'family': 'Brown', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-6413-2454', 'authenticated-orcid': False, 'given': 'Jie', 'family': 'Zhou', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4450-5911', 'authenticated-orcid': False, 'given': 'Nazia', 'family': 'Thakur', 'sequence': 'additional', 'affiliation': []}, {'given': 'Joseph', 'family': 'Newman', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4591-6026', 'authenticated-orcid': False, 'given': 'Ruthiran', 'family': 'Kugathasan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ksenia', 'family': 'Sukhova', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-9878-4007', 'authenticated-orcid': False, 'given': 'Myrsini', 'family': 'Kaforou', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-5640-2266', 'authenticated-orcid': False, 'given': 'Dalan', 'family': 'Bailey', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3948-0895', 'authenticated-orcid': False, 'given': 'Wendy S', 'family': 'Barclay', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2021.12.31.474653', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 4]], 'date-time': '2022-01-04T02:25:13Z', 'timestamp': 1641263113000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 1, 3]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1101/2021.12.31.474653', 'relation': {}, 'published': {'date-parts': [[2022, 1, 3]]}, 'subtype': 'preprint'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit